Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-01-02
2007-01-02
Nguyen, Dave Trong (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S455000, C435S069100, C435S456000, C435S325000, C435S366000
Reexamination Certificate
active
10049502
ABSTRACT:
The protein RhoB and its variants as a supressor of cancer cell growth, inhibitor of malignant cell transformation, and modulator of oncogenic signaling, wherein introducing RhoB directly, or indirectly via a nucleic acid, into a malignantly transformed cell or a cancerous cell decreases phosphorylation of Erk and Akt proteins inhibiting the PI3-kinase/Akt cell survival pathway and promoting apoptotic cell death. Methods and compositions are disclosed for administering to cancer patients, a prophylactic treatment to minimize the risk of malignant transformation, and advantageous combination of RhoB therapy with existing cancer treatments. The protein RhoB and the variants of the present invention are prenylated with either geranylgeranyl or farnesyl, and provision is made for selection of the prenylating moiety.
REFERENCES:
patent: 2002/0034725 (2002-03-01), McKenna et al.
patent: 2004/0171547 (2004-09-01), Sebti
Chen et al Both Farnesylated and Geranylgeranylated RhoB Inhibit Malignant transformation and Suppress Human Tumor Growth in Nude Mice, JBC vol. 275(24) pp. 17974-17978, 2000.
Liu and Jessell, A role for rhoB in the delamination of neural crest cells from the dorsal beural tube, Development, 1998, col. 125, pp. 5055-5067.
Lebowitz et al, Farnesyltransferase Inhibitors Alter the Prenylations and Growth-stimulating Function of RhoB, JBC, 1997, vol. 272(25), pp. 15591-15594.
Meng and El-Deiry, Tumor Suppressor Genes as Targets for Cancer Gene Therapy, Gene Therapy of Cancer, Chapter 1, pp. 3-18.
Verma and Somia, Gene therapy-promises, problems and prospects, Nature, Sep. 1997, vol. 389, pp. 239-242.
Marshall, Second Child in French Trial is FOund to Have aleukemia, Science, Jan. 2003, vol. 299, p. 320.
Torchilin and Lukyanov, Peptide and protein drug delivery to and into tumors: challenges and solutions, Drug Discovery Today, Mar. 2003, vol. 8 pp. 259-265.
Gura et al, Systems for Identifying New Drugs are Often Faulty, Sicence, 1997, vol. 278, pp. 1041-1042.
McCormick, F.Nature363: 15-16 (1993).
Campbell, S.L. et al.,Oncogene17:1395-1413 (1998).
Zohn, I.M., et al.,Oncogene17: 1415-1438 (1998).
Barbacid, M.,Annu. Rev. Biochem., 56:779-827 (1987).
Bos, J.L.,Cancer Res. 49:4682-4689, (1989).
Olson, M.F., et al.,A. Science269:1270-1272 (1995).
Khosravi-Far, R. et al.,Mol. Cell. Biol. 15:6443-6453 (1995).
Qiu, R. G., et al.,Nature374:457-459 (1995).
Mellor, H. et al.,J. Biol. Chem. 273:4811-4814 (1998).
Jahner, D. et al.,Mol. Cell. Biol. 11:3682-3690 (1991).
Fritz, G., et al.,J. Biol. Chem. 270:25172-25177 (1995).
Zhang, F.L., et al.,Annu. Rev. Biochem. 65:241-269 (1996).
Lebowitz, P.F., et al.,J. Biol. Chem. 272:15591-15594 (1997).
Sebti, S.M., et al.,Pharmacol. Ther. 74:103-114 (1997).
Gibbs, J.B., et al.,Annu. Rev. Pharmacol. Toxicol. 37:143-166 (1997).
Cox, A.D., et al.,Biochem. Biophys. Acta1333:F51-F71 (1997).
Lebowitz, P.F., et al.,Oncogene17:1439-1445 (1998).
Chen, Z. et al., Farnesylated and Geranylgeranylated RhoB Suppress the Transformation of PANC-1 Human Pancreatic Concerl Cells; Proceedings of the 91stAnnual Meeting of the American Association for Cancer Research, vol. 14, p. 220, abstract No. 1402.
Du, W. et al., Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB, Molecular and Cellular Biology, vol. 19, No. 3, Mar. 1999, pp. 1831-1840. g.
Chen, Z. et al. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice, Journal of Biological Chemistry, vol. 275, No. 24, Jun. 16, 2000, pp. 17974-17978.
U.S. Appl. No. 10/759,328, filed Jan. 16, 2004, Sebti.
Adamson, P. et al. “Post-translational modifications of p21theproteins”J Biol Chem, 1992, 267:20033-20038.
Adnane, J. et al. “RhoB, not RhoA, represses the transcription of the transforming growth factor β type II receptor by a mechanism involving activator protein 1”J Biol Chem, 2002, 277:8500-8507.
Armstrong, S.A. et al. “CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB”J Biol Chem, 1995, 270:7864-7868.
Baron, R. et al. “RhoB prenylation is driven by the three carboxylterminal amino acids of the protein: Evidencedin vivoby an anti-farnesyl cysteine antibody”Proc Natl Acad Sci USA, 2000, 97:11626-11631.
Chang, F. et al. “Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention”Leukemia, 2003, 17:1263-1293.
Chardin, P. et al. “Coding sequence of humanrhocDNAs clone 6 and clone 9”Nucleic Acids Res. 1988, 16: 2717.
Clark, E.A. et al. “Genomic analysis of metastasis reveals an essential role for RhoC”Nature, 2000, 406:532-535.
Downward, J. “Targeting Ras signaling pathways in cancer therapy”Nat Rev Cancer, 2003, 3:11-22.
Forget, M.A. et al. “The expression of Rho proteins decreases with human brain tumor progression: potential tumor markers”Clin Exp Metastasis, 2002, 19(1):9-15.
Fritz, G. and Kaina, B. “Ras-related GTPase RhoB represses NF-xB signaling”J Biol Chem, 2001, 276:3115-3122.
Fukata, M. et al. “Roles of Rho-family GTPases in cell polarisation and directional migration”Curr Opin Cell Biol, 2003, 15:590-597.
Genbank accession No. X06820, “H sapiens rhoB gene mRNA” Oct. 24, 1996.
Genbank accession No. CAA29968, “rhoB [Homo sapiens]” Oct. 24, 1996.
Jiang, K. et al. “Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis”Mol Cell Biol, 2004, 24:5565-5576.
Jiang, K. et al. “EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation”Oncogene, 2004, 23:1136-1145.
Liu, A-X, et al, “RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells”Mol Cell Biol, 2001, 21:6906-6912.
Mazieres, J. et al. “Loss of RhoB expression in human lung cancer progression”Clin Cancer Res, 2004, 10:2742-2750.
Nakamura, T. et al. “Cloning of the RhoB gene from the mouse genome and characterization of its promoter region”Biochem. Biophys. Res. Commun., 1996, 226(3):688-694.
Nobes, C.D. and Hall, A. “Rho, Rac, and Cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia”Cell, 1995, 81:53-62.
Symons, M. and Rusk, N. “Control of vesicular trafficking by Rho GtPases”Curr Biol, 2003, 13:R409-418.
Wang, D-A and Sebti, S.M. “Palmitoylated cysteine 192 is required for RhoB tumor suppressive and apoptotic activities” Presentation at the American Association for Cancer Research, Anaheim, CA, Apr. 16-20, 2005, abstract.
Wang, D-A. and Sebti, S.M. “Palmitoylated cysteine 192 is required for RhoB tumor-suppressive and apoptolic activities”J. Biol. Chem., 2005, 280:19243-19249.
Welsh, C.F. “Rho GTPases as key transducers of proliferative signals in G1cell cycle regulation”Breast Cancer Res Treat, 2004, 84:33-42.
U.S. Appl. No. 11/274,368, filed Nov. 14, 2005, Sebti.
Adnane, J. et al. “Suppression of Rho B expression in invasive carcinoma from head and neck cancer patients”Clin Cancer Res, 2002, 8:2225-2232.
Alimandi, M. et al. “Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas”Oncogene, 1995, 10:1813-1821.
Arboleda, M.J. et al. “Overexpression of AKT2/protein kinase Bβ leads to up-regulation of β1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells”Cancer Res, 2003, 63:196-206.
Buday, L. and Downward, J. “Epidermal growth factor regulates p21thethrough the formation of a complex of receptor, Grb2 adaptor protein, and Sos nucleotide ex
Marvich Maria
Nguyen Dave Trong
Saliwanchik Lloyd & Saliwanchik
University of South Florida Board of Trustees
LandOfFree
Rhob as a suppressor of cancer cell growth and cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rhob as a suppressor of cancer cell growth and cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rhob as a suppressor of cancer cell growth and cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3821908